Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis

There are no published clinical reports comparing ibandronate (IBN) treatment and zoledronic acid (ZOL) treatment in Japanese postmenopausal osteoporotic patients. This investigation therefore compared the efficacy and safety of the drugs on improving bone metabolism and bone mineral density (BMD) i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Masashi Uehara, Yukio Nakamura, Takako Suzuki, Masaki Nakano, Jun Takahashi
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	bone mineral density efficacy ibandronate zoledronic acid osteoporosis Medicine R
Acceso en línea:	https://doaj.org/article/6a4c544b7a464b6785916b23d520d326
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6a4c544b7a464b6785916b23d520d326
record_format	dspace
spelling	oai:doaj.org-article:6a4c544b7a464b6785916b23d520d3262021-11-25T18:02:38ZEfficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis10.3390/jcm102254202077-0383https://doaj.org/article/6a4c544b7a464b6785916b23d520d3262021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/22/5420https://doaj.org/toc/2077-0383There are no published clinical reports comparing ibandronate (IBN) treatment and zoledronic acid (ZOL) treatment in Japanese postmenopausal osteoporotic patients. This investigation therefore compared the efficacy and safety of the drugs on improving bone metabolism and bone mineral density (BMD) in Japanese postmenopausal women with primary osteoporosis. Eighty-two treatment-naïve primary osteoporotic female patients were randomly divided into IBN-treated or ZOL-treated groups. Bone turnover markers and BMD were examined immediately prior to treatment (baseline) and at 6, 12, 18, 24, and 30 months of therapy. Compared with baseline levels, the values of type 1 procollagen N-terminal propeptide, bone-specific alkaline phosphatase (BAP), urinary type-I collagen amino-terminal telopeptide (NTX), and tartrate-resistant acid phosphatase 5b were all significantly decreased at every time point in both groups apart from BAP at 30 months in the ZOL group, urinary NTX at 12 months in the ZOL group and at 24 and 30 months in both groups. Lumbar BMD values were significantly increased at 6, 12, 18, and 24 months in the IBN group and at 6 and 12 months in the ZOL group compared with pre-treatment levels. Hip BMD values were also significantly increased at 6, 12, 18, and 24 months in the IBN group and at 6, 12, and 18 months in the ZOL group compared with baseline values. The percentage changes of hip BMD at 18 and 24 months in the ZOL group were significantly higher than those in the IBN group (both <i>p</i> < 0.05). No remarkable adverse events were noted in either group. In conclusion, both IBN and ZOL significantly and safely improved bone turnover markers and BMD during 30 months of treatment in Japanese osteoporosis patients. The ZOL group tended to exhibit greater gains in BMD as compared with the IBN group, which merits further investigation.Masashi UeharaYukio NakamuraTakako SuzukiMasaki NakanoJun TakahashiMDPI AGarticlebone mineral densityefficacyibandronatezoledronic acidosteoporosisMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5420, p 5420 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	bone mineral density efficacy ibandronate zoledronic acid osteoporosis Medicine R
spellingShingle	bone mineral density efficacy ibandronate zoledronic acid osteoporosis Medicine R Masashi Uehara Yukio Nakamura Takako Suzuki Masaki Nakano Jun Takahashi Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
description	There are no published clinical reports comparing ibandronate (IBN) treatment and zoledronic acid (ZOL) treatment in Japanese postmenopausal osteoporotic patients. This investigation therefore compared the efficacy and safety of the drugs on improving bone metabolism and bone mineral density (BMD) in Japanese postmenopausal women with primary osteoporosis. Eighty-two treatment-naïve primary osteoporotic female patients were randomly divided into IBN-treated or ZOL-treated groups. Bone turnover markers and BMD were examined immediately prior to treatment (baseline) and at 6, 12, 18, 24, and 30 months of therapy. Compared with baseline levels, the values of type 1 procollagen N-terminal propeptide, bone-specific alkaline phosphatase (BAP), urinary type-I collagen amino-terminal telopeptide (NTX), and tartrate-resistant acid phosphatase 5b were all significantly decreased at every time point in both groups apart from BAP at 30 months in the ZOL group, urinary NTX at 12 months in the ZOL group and at 24 and 30 months in both groups. Lumbar BMD values were significantly increased at 6, 12, 18, and 24 months in the IBN group and at 6 and 12 months in the ZOL group compared with pre-treatment levels. Hip BMD values were also significantly increased at 6, 12, 18, and 24 months in the IBN group and at 6, 12, and 18 months in the ZOL group compared with baseline values. The percentage changes of hip BMD at 18 and 24 months in the ZOL group were significantly higher than those in the IBN group (both <i>p</i> < 0.05). No remarkable adverse events were noted in either group. In conclusion, both IBN and ZOL significantly and safely improved bone turnover markers and BMD during 30 months of treatment in Japanese osteoporosis patients. The ZOL group tended to exhibit greater gains in BMD as compared with the IBN group, which merits further investigation.
format	article
author	Masashi Uehara Yukio Nakamura Takako Suzuki Masaki Nakano Jun Takahashi
author_facet	Masashi Uehara Yukio Nakamura Takako Suzuki Masaki Nakano Jun Takahashi
author_sort	Masashi Uehara
title	Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
title_short	Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
title_full	Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
title_fullStr	Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
title_full_unstemmed	Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
title_sort	efficacy and safety of oral ibandronate versus intravenous zoledronic acid on bone metabolism and bone mineral density in postmenopausal japanese women with osteoporosis
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/6a4c544b7a464b6785916b23d520d326
work_keys_str_mv	AT masashiuehara efficacyandsafetyoforalibandronateversusintravenouszoledronicacidonbonemetabolismandbonemineraldensityinpostmenopausaljapanesewomenwithosteoporosis AT yukionakamura efficacyandsafetyoforalibandronateversusintravenouszoledronicacidonbonemetabolismandbonemineraldensityinpostmenopausaljapanesewomenwithosteoporosis AT takakosuzuki efficacyandsafetyoforalibandronateversusintravenouszoledronicacidonbonemetabolismandbonemineraldensityinpostmenopausaljapanesewomenwithosteoporosis AT masakinakano efficacyandsafetyoforalibandronateversusintravenouszoledronicacidonbonemetabolismandbonemineraldensityinpostmenopausaljapanesewomenwithosteoporosis AT juntakahashi efficacyandsafetyoforalibandronateversusintravenouszoledronicacidonbonemetabolismandbonemineraldensityinpostmenopausaljapanesewomenwithosteoporosis
_version_	1718411683827810304

Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis

Ejemplares similares